Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc
Download Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc full books in PDF, epub, and Kindle. Read online Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC by : Anthony Faber
Download or read book Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC written by Anthony Faber and published by Academic Press. This book was released on 2023-01-30 with total page 150 pages. Available in PDF, EPUB and Kindle. Book excerpt: Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance
Book Synopsis Acquired Resistance to Targeted Therapy in EGFR-mutant Lung Adenocarcinoma by : Caroline Amalia Nebhan
Download or read book Acquired Resistance to Targeted Therapy in EGFR-mutant Lung Adenocarcinoma written by Caroline Amalia Nebhan and published by . This book was released on 2014 with total page 145 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Third Generation EGFR Inhibitors by : Harun M. Patel
Download or read book Third Generation EGFR Inhibitors written by Harun M. Patel and published by Elsevier. This book was released on 2018-11-27 with total page 210 pages. Available in PDF, EPUB and Kindle. Book excerpt: Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and the possibilities of them overcoming constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors, reviewing both their design strategies and typical anticancer activity
Book Synopsis Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Cells Harboring Activating EGFR Mutation by : 黃銘宏
Download or read book Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Cells Harboring Activating EGFR Mutation written by 黃銘宏 and published by . This book was released on 2021 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Therapeutic Strategies in EGFR Mutant Lung Cancer by : Yaxiong Zhang
Download or read book Therapeutic Strategies in EGFR Mutant Lung Cancer written by Yaxiong Zhang and published by Frontiers Media SA. This book was released on 2022-11-03 with total page 239 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis EGFR-Directed Therapy in Lung Cancer by : So Yeon Kim
Download or read book EGFR-Directed Therapy in Lung Cancer written by So Yeon Kim and published by Cambridge University Press. This book was released on 2023-01-26 with total page 72 pages. Available in PDF, EPUB and Kindle. Book excerpt: Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).
Book Synopsis Successes and Limitations of Targeted Cancer Therapy by : S. Peters
Download or read book Successes and Limitations of Targeted Cancer Therapy written by S. Peters and published by Karger Medical and Scientific Publishers. This book was released on 2014-02-19 with total page 126 pages. Available in PDF, EPUB and Kindle. Book excerpt: The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies.
Book Synopsis Critical Issues in Head and Neck Oncology by : Jan B. Vermorken
Download or read book Critical Issues in Head and Neck Oncology written by Jan B. Vermorken and published by Springer Nature. This book was released on 2023-03-27 with total page 361 pages. Available in PDF, EPUB and Kindle. Book excerpt: This is an open access book. With a wealth of exciting data emerging in this rapidly evolving field this book will review the state-of-the-art knowledge with emphasis on multidisciplinary decision and management of head and neck cancer. The book provides significant detail on a wide range of topics including: the role of new targets for treatment, immunotherapy, resistance mechanisms, standardizing molecular profiling programs, and new methods to guide therapeutic approaches. In addition different disease situations are addressed including different treatment approaches in primary disease and in recurrent and/or metastatic disease as well as new developments in pathology, surgery and reconstruction techniques, new systemic therapies in salivary gland cancer, and supportive care and follow-up. All disciplines involved in the treatment of head & neck cancer are covered with a focus on translation into daily practice. The 8th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment of patients with head and neck cancer.
Book Synopsis Optimizing the Sequence of Targeted Therapy in EGFR-mutant Lung Adenocarcinoma by : Catherine Belle Meador
Download or read book Optimizing the Sequence of Targeted Therapy in EGFR-mutant Lung Adenocarcinoma written by Catherine Belle Meador and published by . This book was released on 2015 with total page 228 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Molecular Pathology of Lung Cancer by : Philip T. Cagle
Download or read book Molecular Pathology of Lung Cancer written by Philip T. Cagle and published by Springer Science & Business Media. This book was released on 2012-06-14 with total page 217 pages. Available in PDF, EPUB and Kindle. Book excerpt: As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.
Download or read book Rapid Drug Design written by and published by Drug design by computers. This book was released on with total page 145 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Exploitation and Mechanistic Validation of Drug-combination Strategies to Overcome EGFR-inhibitor Resistance in NSCLC Cells by : Yu-Chieh Wang
Download or read book Exploitation and Mechanistic Validation of Drug-combination Strategies to Overcome EGFR-inhibitor Resistance in NSCLC Cells written by Yu-Chieh Wang and published by . This book was released on 2008 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Abstract: Pre-existing and acquired resistance to epidermal growth factor receptor (EGFR) inhibitors limits their clinical usefulness in patients with advanced non-small cell lung cancer (NSCLC). In this dissertation research work, the in vitro/in vivo efficacy and mechanisms of the combination of gefitinib or erlotinib with OSU-03012, a celecoxib-derived antitumor agent, to overcome EGFR inhibitor-resistance in three NSCLC cell lines, H1155, H23, and A549, are characterized. The OSU-03012/EGFR inhibitor combination induced pronounced apoptosis in H1155 and H23 cells, but not in A549 cells, suggesting a correlation between drug sensitivity and basal phospho-Akt levels independently of EGFR expression status. Evidence indicates that this combination facilitates apoptosis through both Akt signaling inhibition and upregulation of ER stress-induced, GADD153-mediated pathways. For example, ectopic expression of constitutively active Akt significantly attenuated the inhibitory effect on cell survival, and siRNA-mediated knockdown of GADD153 protected cells from undergoing apoptosis in response to drug co-treatments. Furthermore, the OSU-03012/EGFR inhibitor combination induced GADD153-mediated upregulation of death receptor 5 expression and subsequent activation of the extrinsic apoptosis pathway. It is noteworthy that the ER stress response induced by this combination was atypical in that the cytoprotective pathway was not engaged. In addition, in vivo suppression of tumor growth and modulation of intratumoral biomarkers were observed in a H1155 tumor xenograft model in nude mice. These data suggest that the concomitant modulation of Akt and ER stress pathways with the OSU-03012/EGFR inhibitor combination represents a unique approach to overcoming EGFR inhibitor resistance in NSCLC and perhaps other types of cancer with elevated basal Akt activities. In addition to the OSU-03012/EGFR inhibitor combinations, erlotinib in combination with HDAC inhibitor vorinostat or OSU-HDAC42 exhibits significantly enhanced anticancer activity in two EGFR-inhibitor resistant NSCLC cell lines, H1299 and H1975, by targeting signaling involved in regulation of cell survival and death at multiple levels. The erlotinib/HDAC inhibitor combination elicited massive apoptosis in both of H1299 and H1975 cell lines, suggesting that the anticancer activity of this combination strategy is independent of p53 function and EGFR mutations. Evidence indicates that this combination facilitates apoptosis through inhibition of Akt and Erk survival signaling and activation of NR4A1-mediated apoptosis. The studies presented here provide novel mechanistic rationales for the clinical use of EGFR inhibitors to possibly form more effective protocols for treating NSCLC patients.
Book Synopsis Pocket Oncology by : Alexander Drilon
Download or read book Pocket Oncology written by Alexander Drilon and published by Lippincott Williams & Wilkins. This book was released on 2014 with total page 352 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pocket Oncology, developed and edited by oncologists at Memorial Sloan-Kettering Cancer Center, is a simple, yet comprehensive, review of basic principles of cancer management. Prepared in the style and format of books in the popular Pocket Notebook series, Pocket Oncology is intended as a quick reference presented in easy to read bulleted text, and using diagrams and charts where appropriate. Each oncologic disease is presented on two facing pages that review initial clinical presentation, pathophysiology, staging, current standard of care treatments, and active areas of current research. Edited by Alexander Drilon and Michael Postow, the content of the book has been written by medical oncology fellows and each disease entity has been authoritatively reviewed by an oncologist with specific expertise in each subspecialty of oncology. Features: -simple, comprehensive, review of basic principles of oncology in easy to read bulleted text, using diagrams and charts where appropriate. -its small size makes it easy to carry the pocket of a lab coat for quick reference to information while in the hospital or oncology clinic. -perfect for medical students, residents, fellows, physician assistants, and nurses who perform daily oncologic care.
Book Synopsis Current Applications for Overcoming Resistance to Targeted Therapies by : Myron R. Szewczuk
Download or read book Current Applications for Overcoming Resistance to Targeted Therapies written by Myron R. Szewczuk and published by Springer. This book was released on 2019-07-15 with total page 320 pages. Available in PDF, EPUB and Kindle. Book excerpt: Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
Book Synopsis Targeted Therapies for Lung Cancer by : Ravi Salgia
Download or read book Targeted Therapies for Lung Cancer written by Ravi Salgia and published by Springer. This book was released on 2019-06-26 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
Book Synopsis Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy by :
Download or read book Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy written by and published by Academic Press. This book was released on 2018-11-21 with total page 294 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment
Book Synopsis Study of Molecular Mechanisms of Sensitivity and Resistance to EGFR-Targeted Therapy in Lung Cancer by : Zhenfeng Zhang
Download or read book Study of Molecular Mechanisms of Sensitivity and Resistance to EGFR-Targeted Therapy in Lung Cancer written by Zhenfeng Zhang and published by . This book was released on 2010 with total page 143 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer is still the leading cause of cancer-related death worldwide. EGFR-targeted tyrosine kinase inhibitors (TKI), such as erlotinib and gefitinib, have dramatic clinical effects on EGFR-dependent lung cancers and are used as first-line therapy for patients with EGFR-mutant lung tumors. However, eventually all tumors acquire secondary resistance to the drugs and progress. Sensitivity to such EGFR-TKI is determined by activating mutations in EGFR tyrosine kinase domain whereas resistance to the TKI can be conferred by EGFR secondary mutations such as EGFR T790M and MET activation. Using a T790M-mutant H1975 NSCLC cell line which is gefitinib-resistant but sensitive to an irreversible EGFR inhibitor CL-387,785 allowed us to compare the target gene changes by treatment with gefitinib or CL387,785 in a transcriptional profiling study. We identified several dual specificity phosphatases (DUSPs) among the most highly and immediately regulated genes upon EGFR inhibition. DUSPs act as natural terminators of MAPK signal transduction and we demonstrate a tumor suppressive role of DUSP6 via targeting ERK activity. We also show that the regulation of DUSP6 is mediated at the promoter level by ETS1, a well-known nuclear target of activated ERK, indicating an important negative feedback loop in NSCLC. Furthermore, we developed an erlotinib-resistant NSCLC cell model and explored mechanisms of such resistance. We discover a novel mechanism of erlotinib resistance involving overexpression of AXL. Further studies confirm that co-treatment using erlotinib along with AXL knockdown or pharmacological inhibition resensitizes these resistant cells leading to cell death. These results suggest that an oncogenic switch from EGFR-dependent to EGFR/AXL-codependent signaling can lead to secondary EGFR-TKI resistance in NSCLC. In summary, our findings provide novel options for the improved targeting of EGFR-dependent tumors by the identification of DUSP6 and AXL as important modulators of EGFR sensitivity/resistance.
